The New Math of Healthcare Growth

Good morning, ! Healthcare’s next growth cycle is looking less like a land grab — and more like a math problem.

Provider consolidation is slowing, employers are staring at healthcare costs approaching $20,000 per worker, and AI is moving from experimentation into the heart of pharma workflows. Different corners of healthcare, same underlying shift: growth alone is no longer enough. Capital and technology increasingly need to prove their ROI.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

Provider Consolidation Hits the Brakes

Healthcare services became a PE favorite during the post-pandemic deal boom, as sponsors raced to consolidate fragmented physician practices and other provider categories. But the market has since reset. After peaking in 2021, quarterly deal activity has trended materially lower, with Q2 2026 deal count down 18.5% YoY and H1 deal value falling 7.3%.

The slowdown is particularly visible in physician practice management companies (PPMs), the sector’s largest segment, where Q2 deal activity declined 35.8% YoY. Higher financing costs are only part of the story: softer healthcare utilization and increasing state scrutiny of PE ownership, MSO structures and physician-practice transactions are making traditional roll-ups more difficult to execute.

Still, activity remains resilient in pockets such as ASCs, clinical staffing and diagnostic laboratories.

Bottom line: Provider consolidation is not disappearing—it is becoming more selective. The next phase will reward platforms that can generate organic growth and operational efficiencies rather than relying primarily on acquisition volume and multiple arbitrage.

Read more

HEALTHTECH CORNER

Pharmacovigilance is becoming an AI problem

Pharmacovigilance is moving from a largely manual compliance function to an increasingly automated intelligence layer for pharma. The pressure is straightforward: the FDA’s FAERS recorded more than 2.1M potential safety signals in 2023, versus ~780,000 in 2011, while adverse-event data continues to proliferate across literature, EHRs and real-world sources.

AI is now being deployed across the workflow. NLP can extract adverse events from unstructured data, ML can support seriousness and duplicate detection, while generative and agentic AI are beginning to automate narrative drafting, coding and workflow orchestration. In literature review, medically tuned AI has reportedly reduced human review time by 88–92%, while pushing accuracy above 96%.

The investment angle is becoming clearer. The global pharmacovigilance automation market is estimated at $3.03B in 2026 and projected to reach $5.68B by 2031, implying a 13.42% CAGR.

Bottom line: the opportunity is not simply automating back-office work. It is reallocating scarce clinical talent—from data processing toward signal validation, benefit-risk assessment and strategic decision-making. But in a highly regulated function, explainability, validation and human oversight will determine which AI platforms actually scale.

Read more

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

Trend to watch

The $19,000 Employee Healthcare Bill

Employer healthcare inflation is becoming structural. Aon projects average costs will rise 9.5% in 2027, pushing spending above $19,000 per employee after four consecutive years of near double-digit increases.

The pressure is increasingly forcing employers to question what belongs in the benefits package. GLP-1s are the clearest test case. Roughly 1 in 8 adults now use the drugs for weight loss, with brand-name injectables costing $1,000 to $1,500 per month and employers potentially absorbing 70% to 100% of that expense. Employers are responding with tighter eligibility, pharmacy management programs, and in some cases, dropping weight-loss coverage entirely.

Why it matters: Employers are shifting from broad benefit expansion toward active utilization and pharmacy cost management. That raises the bar for drugmakers and benefits vendors. Expensive therapies will increasingly need to demonstrate measurable downstream savings, not simply clinical efficacy.

Bottom line: The next employer healthcare battleground is ROI. As costs approach $20,000 per worker, benefits without a defensible economic case become harder to protect. (More)

COMPETITIVE LANDSCAPE SNAPSHOT

INTERESTING ARTICLES